CXSL2300877 | 重组抗CD20人源化单克隆抗体皮下注射液 | Recombinant anti-CD20 humanized monoclonal antibody | Injection | Biological Products(1) | New Drug Application | 2023-12-22 | | Shanghai Shangyao Cross Linked Pharmaceutical Technology Co Ltd | | | view |
CXSL2300798 | 重组抗CD20人源化单克隆抗体皮下注射液 | Recombinant anti-CD20 humanized monoclonal antibody | Injection | Biological Products(1) | New Drug Application | 2023-11-22 | | Shanghai Shangyao Cross Linked Pharmaceutical Technology Co Ltd | | | view |
CXSL2300427 | 重组抗CD20人源化单克隆抗体皮下注射液 | Recombinant anti-CD20 humanized monoclonal antibody | Injection | Biological Products(1) | New Drug Application | 2023-06-22 | | Shanghai Shangyao Cross Linked Pharmaceutical Technology Co Ltd | | | view |
CXSL2200277 | 重组抗CD20人源化单克隆抗体皮下注射液 | Recombinant anti-CD20 humanized monoclonal antibody | Injection | Biological Products(1) | New Drug Application | 2022-06-16 | | Shanghai Shangyao Cross Linked Pharmaceutical Technology Co Ltd | | | view |
CXSL2000334 | 重组抗CD20人源化单克隆抗体皮下注射液 | Recombinant anti-CD20 humanized monoclonal antibody | Injection | Biological Products(1) | New Drug Application | 2020-11-28 | 上海交联药物研发有限公司 | Shanghai Shangyao Cross Linked Pharmaceutical Technology Co Ltd | In Review | 2020-11-27 | view |